Rectal Cancer Clinical Trial
Official title:
(MansTaTME) Trans-anal Versus Laparoscopic Total Mesorectal Excision for Mid and Low Rectal Cancer
This study is designed to assess the surgical, oncological and functional outcome of either the laparoscopic or trans-anal TME in management of mid and low rectal cancer.
Colorectal cancer (CRC) is considered the third most common type of cancer all over the world
and the fourth common cause of cancer-specific mortality.Surgical management for rectal
cancer is challenging due to the narrow pelvis and extreme proximity to contiguous organs
hence, recurrence rates are commonly reported.
The advent of total mesorectal excision (TME) together with minimally invasive techniques
such as laparoscopic colorectal surgery have not only improved surgical results but have also
improved surgical technique, operative ability and surgical visibility. Lap TME has been
shown to give similar results to the classical open approach with regard to peri-operative
morbidity, surgical margins, quality of the surgical specimen, and number of resected lymph
nodes, local recurrence and overall survival.
However, laparoscopic resection of mid and low rectal cancer is technically difficult due to
tapering of the mesorectum in the pelvis and the forward angle of the distal rectum rendering
this part of the rectum less accessible from the abdominal cavity. This may lead to
incomplete mesorectal excision and involved circumferential resection margins (CRMs), with
consequent local recurrences.Previous pelvic radiation can make laparoscopic pelvic
dissection more difficult, and tumors located on the anterior rectal wall have an increased
risk of inadequate oncological clearance. The use of laparoscopic staplers in a narrow pelvis
is difficult and the multiple firings of staples across the low rectum is of concern.
Trans-anal Total Mesorectal Excision (TaTME) was recently developed to overcome technical
difficulties associated with Lap TME and open TME. It may address some of the difficult
aspects of laparoscopic or open TME, such as exposure, rectal dissection, and distal
cross-stapling of the rectum and sphincter preservation. It does not only facilitate
dissection of the difficult distal part of the TME dissection in the narrow pelvis but it
also allows clear definition of safe, tumor-free, radial and longitudinal margins. Moreover,
the specimen could be extracted through the anus excluding the need for minilaparotmy.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06380101 -
Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC)
|
N/A | |
| Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
| Recruiting |
NCT04323722 -
Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04088955 -
A Digimed Oncology PharmacoTherapy Registry
|
||
| Active, not recruiting |
NCT01347697 -
Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer
|
N/A | |
| Recruiting |
NCT04495088 -
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer
|
Phase 3 | |
| Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
| Terminated |
NCT01347645 -
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT03520088 -
PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS
|
N/A | |
| Recruiting |
NCT05556473 -
F-Tryptophan PET/CT in Human Cancers
|
Phase 1 | |
| Recruiting |
NCT04749381 -
The Role of TCM on ERAS of Rectal Cancer Patients
|
Phase 2 | |
| Enrolling by invitation |
NCT05028192 -
Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
|
||
| Recruiting |
NCT03283540 -
Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
|
||
| Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
| Recruiting |
NCT05914766 -
An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer
|
N/A | |
| Recruiting |
NCT04852653 -
A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer
|
||
| Recruiting |
NCT03190941 -
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
|
Phase 1/Phase 2 | |
| Terminated |
NCT02933944 -
Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer
|
Phase 1 | |
| Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A |